The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Long-term follow-up of the GAIA/CLL13 trial: investigating venetoclax-containing combinations in CLL
Kerry Rogers, MD, Ohio State University, Columbus, OH, discusses insights provided by the GAIA/CLL13 study (NCT02950051) on the use of venetoclax in patients with chronic lymphocytic leukemia (CLL). The results demonstrated that a venetoclax plus obinutuzumab combination therapy was superior to venetoclax plus rituximab, leading Dr Rogers to consider whether this combination should be preferentially selected in the relapsed/refractory (R/R) setting. Dr Rogers also touches upon the results of the study arm investigating a three-drug combination of ibrutinib, venetoclax, and obinutuzumab and emphasizes the importance of long-term follow-up data from large randomized trials such as this one. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
